Keytruda, also known as pembrolizumab, is a drug used to treat various types of cancer, including melanoma, lung cancer, and bladder cancer. It is a type of immunotherapy that works by blocking a protein called PD-1, which can help the immune system recognize and attack cancer cells [1].

According to a study published in the New England Journal of Medicine, Keytruda has shown long-term benefits in treating advanced melanoma. The study found that after five years of treatment, 34% of patients who received Keytruda were still alive, compared to only 16% of patients who received other treatments [3].

Another study published in the Journal of Clinical Oncology found that Keytruda was effective in treating patients with advanced bladder cancer who had not responded to chemotherapy. The study found that after a year of treatment, 24% of patients who received Keytruda had no evidence of cancer, compared to only 4% of patients who received chemotherapy [2].

Additionally, Keytruda has been approved by the FDA for use in treating various types of cancer, including melanoma, lung cancer, head and neck cancer, and bladder cancer [1].

Overall, Keytruda has shown promising long-term benefits in treating advanced melanoma and bladder cancer. It is important to note that the effectiveness of Keytruda may vary depending on the type and stage of cancer, as well as individual patient factors. It is recommended to speak with a healthcare provider to determine if Keytruda is an appropriate treatment option [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.cancer.gov/news-events/cancer-currents-blog/2023/bladder-cancer-nivolumab-adjuvant-therapy
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132438/